Screening without evidence of efficacy.
作者信息
Law Malcolm
出版信息
BMJ. 2004 Feb 7;328(7435):301-2. doi: 10.1136/bmj.328.7435.301.
Abstract
摘要
相似文献
1
Screening without evidence of efficacy.在没有疗效证据的情况下进行筛查。
BMJ. 2004 Feb 7;328(7435):301-2. doi: 10.1136/bmj.328.7435.301.
2
Solving the overdiagnosis dilemma.解决过度诊断困境。
J Natl Cancer Inst. 2010 May 5;102(9):582-3. doi: 10.1093/jnci/djq119. Epub 2010 Apr 22.
3
[Criteria for using tumor markers. 2: Indications and interpretation].[肿瘤标志物的使用标准。2：适应证与解读]
Fortschr Med. 1996 Mar 10;114(7):38-40.
4
Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum.癌症风险、早期检测及预后的生物标志物：验证难题
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1918-20. doi: 10.1158/1055-9965.EPI-07-2619.
5
[Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].[早期前列腺癌的诊断与治疗。预后改善——并发症减少]
MMW Fortschr Med. 2010 May 13;152(19):36.
6
[Increased carcinoembryonic antigen level: which diagnosis?].
Dtsch Med Wochenschr. 2005 Feb 18;130(7):353.
7
Cancer screening: understanding barriers to optimal use of evidence-based strategies.癌症筛查：了解基于证据的策略优化使用的障碍
J Womens Health (Larchmt). 2007 Jan-Feb;16(1):9-10. doi: 10.1089/jwh.2006.M071.
8
[Biomarker screening for early detection of cancer].[用于癌症早期检测的生物标志物筛查]
Dtsch Med Wochenschr. 2013 Jan;138(1-2):43-5. doi: 10.1055/s-0032-1327370. Epub 2012 Dec 18.
9
Screening trial of blood test for lung cancer is set to start in Scotland.肺癌血液检测筛查试验即将在苏格兰启动。
BMJ. 2012 Mar 26;344:e2312. doi: 10.1136/bmj.e2312.
10
Serum tumour markers in clinical practice. Some general aspects.临床实践中的血清肿瘤标志物。一些一般情况。
Scand J Clin Lab Invest Suppl. 1991;206:6-11.
引用本文的文献
1
[Awareness of clinical relevance of malignant testicular cancer among university students : The value of prevention campaigns].[大学生对睾丸恶性肿瘤临床相关性的认知：预防活动的价值]
Urologe A. 2019 Jul;58(7):790-794. doi: 10.1007/s00120-019-0936-z.
2
The structure and demographic correlates of cancer fear.癌症恐惧的结构及其人口统计学相关因素。
BMC Cancer. 2014 Aug 16;14:597. doi: 10.1186/1471-2407-14-597.
3
QTc interval screening for cardiac risk in methadone treatment of opioid dependence.在美沙酮治疗阿片类药物依赖中进行QTc间期筛查以评估心脏风险。
Cochrane Database Syst Rev. 2013 Jun 20;2013(6):CD008939. doi: 10.1002/14651858.CD008939.pub2.
4
Colorectal cancer screening: why immunochemical fecal occult blood tests may be the best option.结直肠癌筛查：为何免疫化学粪便潜血试验可能是最佳选择。
BMC Gastroenterol. 2012 Dec 29;12:183. doi: 10.1186/1471-230X-12-183.
5
Quality of optometry referrals to neovascular age-related macular degeneration clinic: a prospective study.转诊至新生血管性年龄相关性黄斑变性诊所的验光质量：一项前瞻性研究。
JRSM Short Rep. 2011 Aug;2(8):64. doi: 10.1258/shorts.2011.011042. Epub 2011 Aug 1.
6
How do nurses and teachers perform breast self-examination: are they reliable sources of information?护士和教师如何进行乳房自我检查：他们是可靠的信息来源吗？
BMC Public Health. 2007 Jun 5;7:96. doi: 10.1186/1471-2458-7-96.
7
"It's a maybe test": men's experiences of prostate specific antigen testing in primary care.“这是一项存在不确定性的检查”：男性在初级医疗保健中进行前列腺特异性抗原检测的经历
Br J Gen Pract. 2007 Apr;57(537):303-10.
8
Screening without evidence of efficacy: screening uncertainties concern evidence, efficacy, decisions.无疗效证据的筛查：筛查的不确定性涉及证据、疗效和决策。
BMJ. 2004 Feb 28;328(7438):521; discussion 521-2. doi: 10.1136/bmj.328.7438.521-a.
9
Screening without evidence of efficacy: thyroid ultrasonography is another example.无疗效证据的筛查：甲状腺超声检查是另一个例子。
BMJ. 2004 Feb 28;328(7438):521; discussion 521-2. doi: 10.1136/bmj.328.7438.521.
本文引用的文献
1
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.验证偏倚对通过检测前列腺特异性抗原筛查前列腺癌的影响。
N Engl J Med. 2003 Jul 24;349(4):335-42. doi: 10.1056/NEJMoa021659.
2
Breast self-examination and death from breast cancer: a meta-analysis.乳房自我检查与乳腺癌死亡：一项荟萃分析。
Br J Cancer. 2003 Apr 7;88(7):1047-53. doi: 10.1038/sj.bjc.6600847.
3
Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy.意大利北部一个大都市地区使用前列腺特异性抗原（PSA）检测筛查前列腺癌的人群覆盖率估计。
J Med Screen. 2002;9(4):179-80. doi: 10.1136/jms.9.4.179.
4
Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.一项自然实验，研究积极筛查和治疗对来自西雅图地区和康涅狄格州的两个固定队列中前列腺癌死亡率的影响。
BMJ. 2002 Oct 5;325(7367):740. doi: 10.1136/bmj.325.7367.740.
5
Randomized trial of breast self-examination in Shanghai: final results.上海乳腺自我检查随机试验：最终结果
J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57. doi: 10.1093/jnci/94.19.1445.
6
Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer.临床实践。前列腺特异性抗原检测用于前列腺癌的早期诊断。
N Engl J Med. 2001 May 3;344(18):1373-7. doi: 10.1056/NEJM200105033441806.
7
Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.前列腺癌前列腺切除术后或放疗后的健康结局：前列腺癌结局研究结果
J Natl Cancer Inst. 2000 Oct 4;92(19):1582-92. doi: 10.1093/jnci/92.19.1582.
8
Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).欧洲前列腺癌筛查随机研究（鹿特丹地区）活检结果的预测因素
Prostate. 1999 Jun 1;39(4):316-22. doi: 10.1002/(sici)1097-0045(19990601)39:4<316::aid-pros14>3.0.co;2-o.
9
Testicular cancer: to screen or not to screen?睾丸癌：筛查还是不筛查？
J Med Screen. 1996;3(1):3-6. doi: 10.1177/096914139600300103.
10
Should testicular self examination be recommended?应该推荐睾丸自我检查吗？
J Med Screen. 1996;3(1):2. doi: 10.1177/096914139600300102.
Zotero 插件